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Abstract
Background: The relationship between diabetes and oxidative stress has been previously reported. Exercise
represents a useful non-pharmacological strategy for the treatment in type 2 diabetic (T2DM) patients, but high
intensity exercise can induce a transient inflammatory state and increase oxidative stress. Nutritional strategies that
may contribute to the reduction of oxidative stress induced by acute exercise are necessary. The aim of this study
was to examine if n-3 PUFA supplementation intervention can attenuate the inflammatory response and oxidative
stress associated with high intensity exercise in this population. As a primary outcome, lipoperoxidation
measurements (TBARS and F2-isoprostanes) were selected.
Methods: Thirty T2DM patients, without chronic complications, were randomly allocated into two groups: placebo
(gelatin capsules) or n-3 PUFA (capsules containing 180 mg of eicosapentaenoic acid and 120 mg of docosahexaenoic
acid). Blood samples were collected fasting before and after 8 weeks supplementation. In the beginning and at the
end of protocol, an acute exercise was performed (treadmill), and new blood samples were collected before and
immediately after the exercise for measurements of oxidative stress and high-sensitivity C-reactive protein (hs-CRP).
Results: After the supplementation period, a decrease in triglycerides levels was observed only in n-3 PUFA
supplementation group (mean difference and 95% CI of 0.002 (0.000–0.004), p = 0.005). Supplementation also
significantly reduced TRAP levels after exercise (mean difference and 95% CI to 9641 (− 20,068–39,351) for
− 33,884 (− 56,976 - -10,793), p = 0.004, Cohen’s d effect size = 1.12), but no significant difference was observed in n-3
PUFA supplementation group in lipoperoxidation parameters as TBARS (mean difference and 95% CI to − 3.8 (− 10–2.4)
for − 2.9 (− 1.6–7.4) or F2-isoprostanes (mean difference and 95% CI -0.05 (− 0.19–0.10) for − 0.02 (− 0.19–0.16), p > 0.05
for both.
Conclusion: PUFA n-3 supplementation reduced triglycerides as well as TRAP levels after exercise, without a significant
effect on inflammatory and oxidative stress markers.
This study is registered at ClinicalTrials.gov with the registration number of NCT03182712.
Keywords: Omega-3, Type 2 diabetes, Acute exercise, Oxidative stress, Inflammation
* Correspondence: apfayh@yahoo.com.br
1Departament of Nutrition, Health Sciences Center, Federal University of
State of Rio Grande do Norte, Avenida Senador Salgado Filho, n° 3000, Natal,
RN 59078-970, Brazil
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fayh et al. Journal of the International Society of Sports Nutrition  (2018) 15:18 
https://doi.org/10.1186/s12970-018-0222-2
Background
Hyperglycemia is the hallmark metabolic abnormality as-
sociated with the complications of type 2 diabetes mellitus
(T2DM). High rates of glucose utilization are associated
with incremental free radical formation and protein modi-
fication (by glucose auto-oxidation, protein glycation, and
polyol pathway activation) [1]. The redox imbalance
resulting from the increase of reactive oxygen and nitro-
gen species, and the concomitant lowering of antioxidant
defenses have been associated to micro- and macrovascu-
lar diabetic complications [2, 3]. Nevertheless, the under-
lying mechanisms related to this imbalance are not
entirely clear.
The relationship between hyperglycemia and increased
lipid peroxidation has been previously reported [2, 4, 5].
Elevated levels of thiobarbituric acid reactive substances
(TBARS) have been found in the blood of both type 1
[6] and type 2 [4] diabetic patients. The gold standard
lipid peroxidation marker, F2-isoprostane, a toxic prod-
uct generated by non-enzymatic, free radical-catalyzed
peroxidation of arachidonic acid, has also been shown to
be elevated in plasma and urine of T2DM [6, 7]. Dis-
rupted redox signalling or elevated oxidative stress (from
prolonged periods of hyperglycemia and/or elevated
pro-inflammatory cytokines) is thought to underlie the
vascular dysfunction observed in individuals with glu-
cose intolerance and diabetes [3]. It has also been shown
that individuals with T2DM have more pronounced sys-
temic inflammation and oxidative stress than those with
normal glucose tolerance [8]. In addition, inflammatory
markers, such as high-sensitivity C-reactive protein (hs-
CRP), are associated with higher risk for cardiovascular
diseases and are also important markers for the control
and prevention of diabetes complications [9].
Regular physical exercise and diet represents a useful
non-pharmacological strategy for the prevention and
treatment of T2DM [3]. The beneficial effects of chronic
exercise are associated with improved mitochondrial via-
bility and antioxidant defenses, reducing oxidative stress
and provides acute and chronic benefits [8, 10, 11], how-
ever, high intensity exercise can induce a transient inflam-
matory state and increase oxidative stress [10, 11]. Thus,
nutritional strategies that may contribute to the reduction
of oxidative stress induced by acute exercise may repre-
sent additional advantages to T2DM people.
Among many dietary components and supplements,
studies have demonstrated beneficial effects of Polyunsatur-
ated Fatty Acids Omega-3 (n-3 PUFA) on different condi-
tions, including diabetes [12–14]. These effects include
alterations in lipoprotein metabolism, platelet and endothe-
lial function, and eicosanoid production. N-3 PUFA play an
important role on cell membranes, are considered essential
fatty acids for human beings, and should be provided by
food intake [3]. Although fatty acid unsaturation favors free
radical activity (increasing lipoperoxidation), the available
literature is controversial when it relates to oxidative stress
following n-3 PUFA supplementation [4, 15, 16].
Therefore, the aim of this study was to examine if
n-3 PUFA supplementation intervention can attenuate
the inflammatory response/oxidative stress associated
with high intensity exercise in this population. As a
primary outcome, lipoperoxidation measurements
(TBARS and F2-isoprostanes) were selected. The anti-
oxidant variables (superoxide dismutase, TRAP and
uric acid) were considered secondary outcomes, and
complement the oxidative stress responses. Addition-
ally, biochemical changes in the lipid and glycemic
profile before and after n-3 supplementation were in-
vestigated. We hypothesized that n-3 PUFA supple-




Participants (adult male and female subjects with
T2DM) were recruited via advertising on local newspa-
pers and workplaces. The exclusion criteria were: in use
of aspirin or insulin, HbA1c above 9.0%, dyslipidemia or
having a diagnosis of any complication of diabetes melli-
tus. The study protocol was in accordance with the
Helsinki declaration and was approved by the Clinics
Hospital of Porto Alegre (HCPA) Ethics and Research
Committee (06–222). All subjects gave written, informed
consent before participation.
Study design
This study has a randomized, double blind, parallel group
design. Initially, physical evaluations were carried out, in-
cluding interview with an expert physician and aerobic
power test with electrocardiogram. After that, participants
attended the outpatient clinic on four occasions: 1) An-
thropometric evaluation and blood and urine collections
in fasting; 2) First sub-maximal exercise test and begin-
ning of supplementation; 3) Blood and urine sampling
(fasting) after 8 weeks of supplementation, and 4) Second
sub-maximal exercise test. Figure 1 illustrates the flow-
chart of experimental sessions.
Anthropometric evaluation
During their first visit, the following anthropometric
parameters were evaluated: body mass, height, circumfer-
ences and skinfolds. Body mass (kg) and height (m) was
determined by a digital scale coupled to a stadiometer
Welmy® (W 110 H, Santa Bárbara d’Oeste, SP, Brasil), with
accuracy of 0.1 kg and 0.01 cm, respectively. Body mass
index (BMI, kg/m2) and waist-to-hip ratio was calculated
according to World Health Organization [17]. Body fat
percent was determined by the Jackson & Pollock formula
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[18] and later converted to fat percentage, according to
formula proposed by Siri [19]. All measurements of skin-
folds were made on the right side of the body by using a
compass (Cescorf®) with accuracy of 0.1 mm. After the
supplementation period, body weight was evaluated.
Blood and urine collection
Blood and urine were collected before and after supple-
mentation period, after 12 h fasting, for analysis of total
cholesterol and fractions, triglycerides, HbA1c and gly-
cemia and albuminury (urine), 24 h before each exercise
session. In the day of submaximal exercise, subjects were
in the fed state, and blood collect occurred immediately
before and after exercise (See Fig. 1).
Exercise protocols
Peak oxygen consumption (VO2) and carbon dioxide pro-
duction (VCO2) were measured breath by breath during
the exercise via an automated ergospirometer metabolic
cart (CPX-D, Medical Graphics Corporation, USA). The
equipment was calibrated before each exercise test ac-
cording to the manufacturer’s instructions. O2 and CO2
analyzers were calibrated using gas standards of known
concentrations before each exercise test.
The maximal exercise tests were carried out on a cycle
ergometer (The Byke, Cybex USA). All tests were started at
a 25 W load, with 25 W/min increments until exhaustion,
followed by a 3-min recovery with a 25 W load. Cycling
should be kept between 60 to 90 cpm, on the subject’s most
comfortable cadence [20]. Volunteers were verbally encour-
aged to achieve their best performance during the maximal
exercise test. The criteria used to verify maximal effort
included a respiratory gas exchange ratio ≥ 1.15, a final peak
heart rate at ≥95% of the age-predicted maximum (220-
age) and/or a VO2 plateau through systematic increases in
the workload [21]. Anaerobic threshold was determined by
the second ventilatory threshold (VT2) [22].
All high intensity sub-maximal tests were performed in
the morning, 2 h after the subject’s usual breakfast. Volun-
teers were asked not to have high-intensity physical activ-
ity, caffeine consumption or alcohol ingestion 24 h before
the tests. The tests were performed at an intensity of VT2,
monitored by VO2 during exercise. After a 3-min rest, the
test started. During the first 5 min, the load was increased
to approximately 55% of VT2. The load was then adjusted
to reach 100% of VT2. The subjects continued the exer-
cise for 30 min or until exhaustion [23].
Supplementation
Supplementation was given to the subjects in pharmacy
manufactured capsules. The placebo capsules contained
500 mg of gelatin. The intervention group received n-3
PUFA-enriched capsules containing 180 mg of eicosa-
pentaenoic acid (EPA), 120 mg of docosahexaenoic acid
(DHA) and 2 mg of vitamin E (alpha-tocopherol) [Natura-
lis®, Brazil]. A low concentration of vitamin E was used in
the formulation to prevent n-3 PUFA oxidation, as previ-
ously recommended [24]. Subjects in both groups were
asked to consume three capsules a day (at breakfast, lunch
and dinner), for 8 weeks.
Biochemical analyses
Venous blood samples were taken after fasting from the
antecubital vein in EDTA coated (for plasma) or plain (for
serum) tubes using standard aseptic techniques. Urine
samples for measurement of albuminuria also were col-
lected only before and at the end of the supplementation
period. Total cholesterol, HDL-cholesterol, triglycerides
and glucose were measured by enzymatic colorimetric
assays; Friedewald’s formula was used to calculate for
Fig. 1 Flowchart of experimental sessions
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LDL-cholesterol fraction [25]. Glycated hemoglobin
(HbA1C) was measured by an immunoassay; urinary albu-
min was measured by immunoturbidimetry.
Before and after each submaximal test, blood samples
were immediately centrifuged at 4 °C, 4000 rpm, for 5 min,
and plasma or serum were separated and stored at − 75 °C
for further analysis. We analyzed hs-CRP after each testing
using nephelometry. Lipid Peroxidation was assessed by
two distinct techniques: 1) Plasma F2-isoprostanes analysis,
using a commercial kit (Cayman®), and 2) TBARS analysis,
based in the thiobarbituric acid reactivity with malondialde-
hyde, a lipid oxidation end-product [26]. Non-enzymatic
plasma antioxidant properties were assessed by total react-
ive antioxidant potential (TRAP), determined by chemilu-
minescence [27]. Superoxide dismutase (SOD) activity was
measured indirectly through the inhibition of adrenaline
auto-oxidation to adrenochrome, as described by Bannister
[28]. Plasma protein was determined as described by Lowry
et al. [29]. Uric acid was determined by a commercial kit
Uricostat enzymatic AA, Wiener Lab®, Rosario, Agentina).
Statistical analysis
Data were analyzed on SPSS 25.0 for Windows (IBM,
USA). Normality was assessed by the Shapiro-Wilk
test, and Levene’s test was used for homoscedasticity.
For baseline value comparison between groups,
Student’s t-test for independent samples or the
Mann-Whitney test were performed. A generalized
estimating equation (GEE) followed by Bonferroni’s post
hoc test was used to verify supplementation and exercise
effects adjusted for age, gender, duration of diabetes and
use of drugs. The GEE model for each outcome was based
on the goodness of fit. The normality of the residuals was
verified by normal Q-Q plot. Some cardiometabolic vari-
ables were transformed due to the high variability among
individuals, using a) logarithmic transformation for hs-
CRP and F2-isoprostanes, b) square root transformation
for albuminuria, uric acid and SOD, and c) inverse trans-
formation for triglycerides and HbA1C. Cohen’s d was
used to verify the effect size of the means. The accepted
significance level was p < 0.05. Data were reported as
mean ± standard deviation, and difference mean and 95%
confidence interval (95% CI).
Results
Figure 2 shows the flow diagram of patient recruitment
and randomization. Of the 90 individuals who mani-
fested interest in participating in the study, 60 were
excluded based on the adopted criteria. In total, 30
individuals performed all baseline assessments, and all
subjects completed the intervention. The characteris-
tics of the participants are presented in Table 1.
There were no differences in age, diabetes duration,
weight, height, body mass index, percentage of body
fat and peak oxygen consumption between the
groups. Waist to hip ratio was higher in male subjects
in the n3-PUFA group (p = 0.03).
Fig. 2 Flow diagram of patient recruitment and randomization
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After the supplementation period, individuals did
not change your body weight (0.94 ± 0.36% in n-3
PUFA supplementation and 0.75 ± 0.25% in placebo
group, respectively, p > 0.05 for both). Table 2 shows
the biochemical parameters before and after supple-
mentation period. n-3 PUFA supplementation signifi-
cantly reduced triglycerides by 17% (P = 0.005),
compared with baseline values, and by 26% when
compared with the placebo group (P = 0.05). No other
interaction condition vs time was observed in the ex-
perimental groups.
Regarding submaximal exercise tests, there were no
differences in time duration in both groups before
(14 ± 5.02 min and 15 ± 6.1 min) and after supplemen-
tation (15 ± 4.7 min and 13 ± 5.8 min) for n-3 PUFA sup-
plementation and placebo groups, respectively (p > 0.05).
Table 3 shows the results about oxidative stress and in-
flammation parameters after supplementation and sub-
maximal exercises. No significant changes were observed
for TBARS nor F2-Isoprostanes concentrations (primary
outcome). In the n-3 PUFA supplementation group, a
statistical significant interaction (condition vs time) was
observed for TRAP count values, with decrease after sup-
plementation and exercise. Cohen’s d effect size was con-
sider high for this mean difference (d ≥ 0.8). Although no
statistically significant interaction was found for SOD
levels (p = 0.095), the n-3 PUFA supplementation group
presented an increase after supplementation (p = 0.002,
Cohen’s d effect size = 0.49), with a tendency in their
Table 1 Baseline characteristics of the study groups
n-3 PUFA (n = 15) Placebo (n = 15)
N 15 15
Sex (male/female) 8/7 4/11
Age (years) 50.47 ± 6.06 50.67 ± 6.70
Diabetes Duration (years) 6 (2–15) 8 (1–25)
Drug Treatment (n)







Weight (kg) 77.27 ± 11.65 72.49 ± 7.66
Height (m) 1.65 ± 0.08 1.59 ± 0.09
Body Mass Index (kg.m− 2) 28.22 ± 2.95 28.81 ± 4.10
Body fat (%) 32.93 ± 8.88 33.79 ± 10.07
Waist-to-hip ratio
Men 0.97 ± 0.05a 0.88 ± 0.05
Women 0.83 ± 0.08 0.87 ± 0.05
VO2peak (ml/kg/.min) 22.87 ± 5.42 22.10 ± 6.87
Maximal heart rate (bpm) 151.13 ± 20.29 153.87 ± 19.98
ap = 0.03 with Student’s t-test
Table 2 Cardiometabolic parameters in response to n-3 PUFA or placebo supplementation, in baseline and after 8 weeks (follow up)
n-3 PUFA (n = 15) Placebo (n = 15)
Baseline Follow-up Diff. Mean (95% CI) Baseline Follow-up Diff. Mean (95% CI) P value*
HbA1c (%) 6.11 ± 0.57 6.47 ± 0.86 7.01 ± 1.06 7.40 ± 1.72
Log HbA1c (%)b 0.17 ± 0.01 0.16 ± 0.02 −0.008 (− 0.014 to − 0.002) 0.14 ± 0.02 0.14 ± 0.02 − 0.005 (− 0.020 to 0.010) 0.752
Glucose
(mg/dl)
134.7 ± 10.1 131.1 ± 6.7 − 3.5 (− 0.01 to 4.7) 130.8 ± 5.5 122.8 ± 4.6 −8.0 (− 2.5 to 9.2) 0.382
Triglycerides
(mg/dl)
136.5 ± 75.9 113.3 ± 71.4 152.9 ± 59.5 153 ± 56.4
Log Triglycerides
(mg/dl)b
0.009 ± 0.004 0.011 ± 0.005 0.002 (0.000 to 0.004)** 0.008 ± 0.003 0.008 ± 0.003 0.000 (− 0.001 to 0.001) 0.005
Total Cholesterol
(mg/dl)
182.4 ± 41.3 177.1 ± 44.7 − 5.8 (− 17.8 to 6.1) 192.3 ± 38.2 193.3 ± 40.4 0.7 (− 15.8 to 17.2) 0.385
HDL-cholesterol
(mg/dl)
49.7 ± 15.9 52 ± 15 2.3 (− 0.5 to 5.1) 51.7 ± 12.2 53.9 ± 12.7 2.1 (− 3.0 to 7.2) 0.904
LDL-cholesterol
(mg/dl)
105.4 ± 35.3 102.4 ± 41.4 − 3.9 (− 16.4 to 8.6) 110.0 ± 35.6 108.8 ± 41.7 −1.4 (− 16.9 to 14.1) 0.732
Albuminuria
(mg/dl)
9.67 ± 6.06 8.89 ± 7.04 5.64 ± 3.52 3.99 ± 2.25
Log Albuminuria
(mg/dl)a
2.25 ± 0.59 1.92 ± 0.49 − 0.33 (− 0.73 to 0.07) 2.91 ± 0.82 2.74 ± 1.04 − 0.16 (− 0.93 to 0.60) 0.426
Values are presented as mean ± standard deviation. *Models were adjusted for age, gender, duration of diabetes and use of drugs, Logarithmic transformation,
aSquare root transformation, bInverse transformation, **(p = 0.004 compared to before supplementation
p value in bold was statiscally significant
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concentrations after exercise. There was no significant dif-
ference for hs-CRP between the groups.
Discussion
The main finding of this study was that 8 weeks of n-3
PUFA supplementation reduces TRAP concentration after
a high intensity exercise, with no other statistically signifi-
cant changes in other oxidative stress parameters or inflam-
mation. Additionally, as previously demonstrated, n-3
PUFA supplementation reduced triglycerides levels. Our
hypothesis was partially rejected, due to the fact that our
primary outcomes (TBARS and F2-isoprostanes) were not
attenuated by n-3 PUFA supplementation.
As previously mentioned, physical exercise is considered
a powerful tool to prevent and to treat diabetes and the
associated comorbidities. Nowadays, due to the lack of
time, many people are using high intensity exercise ses-
sions (with a lower volume), as an alternative, to improve
their health, metabolic function and body composition.
However, high intensity exercise can induce a transient in-
flammatory state and increase oxidative stress [10, 11] that
may promote, in diabetic population, an undesired effect.
The increase in VO2 (load dependent) caused by exercise
can lead to increased blood and tissue levels of reactive
oxygen species [30]. Laaksonen et al. [31] and Atalay et al.
[32] showed increased reactive oxygen species production
after 40 min of sub-maximal exercise (intensity equivalent
to 60% of VO2peak) in type 1 diabetic subjects. In our
study, exercise performed with intensity equivalent to 70–
80% of VO2peak was not able to increase the production of
Table 3 Variables of oxidative stress between the groups (n-3 and placebo) and times (pre-exercise and post-exercise)
n-3 PUFA (n = 15) Placebo (n = 15)











us-CRP (mg/dL) 2.88 ± 3.2 3.10 ± 3.35 2.37 ± 2.42 2.56 ± 2.66 3.36 ± 3.39 3.63 ± 3.61 3.19 ± 3.26 3.43 ± 3.51
Log us-PCR (mg/dL)a 0.50 ± 0.29 0.53 ± 0.3 0.45 ± 0.28 0.47 ± 0.28 0.51 ± 0.28 0.49 ± 0.27 0.53 ± 0.29 0.50 ± 0.29 0.712
Diff. Mean (95% CI) 0.02 (0.01 to 0.03) 0.02 (0.01 to 0.04) 0.03 (0.01 to 0.04) 0.02 (0.01 to 0.03)
Cohen’s d 0.10 0.07 0.07 0.10
TBARS (pmolTBARS/
mgPTN)
40.2 ± 20.9 36.7 ± 17 29.7 ± 9.9 32.5 ± 11.8 38.4 ± 19.2 40.0 ± 20.5 37.5 ± 17.7 33.1 ± 11.8 0.052
Diff. Mean (95% CI) −3.8 (− 10 to 2.4) − 2.9 (−1.6 to 7.4) 1.62 (− 1.03 to 4.28) −4.4 (− 10.7 to 1.8)















2.4 ± 0.39 2.36 ± 0.26 2.34 ± 0.34 2.32 ± 0.32 2.37 ± 0.29 2.45 ± 0.25 2.37 ± 0.28 2.30 ± 0.2 0.438
Diff. Mean (95% CI) −0.05 (− 0.19 to 0.10) −0.02 (− 0.19 to 0.16) 0.08 (− 0.05 to 0.21) −0.07 (− 0.18 to 0.04)
Cohen’s d 0.12 0.06 0.26 0.28
Uric Acid (mg/L) 47.5 ± 16.0 48.6 ± 17.7 47.9 ± 19.1 46.9 ± 17.2 38.6 ± 8.1 39.8 ± 7.0 36.2 ± 6.9 36.6 ± 7.3
Log Uric Acid (mg/L)b 6.71 ± 0.91 6.77 ± 1.05 6.70 ± 1.12 6.64 ± 0.99 6.24 ± 0.71 6.36 ± 0.74 6.04 ± 0.64 6.09 ± 0.74 0.639
Diff. Mean (95% CI) 0.06 (− 0.14 to 0.26) −0.06 (− 0.19 to 0.08) 0.12 (− 0.13 to 0.38) 0.04 (− 0.13 to 0.22)
Cohen’s d 0.06 0.06 0.17 0.07

















Diff. Mean (95% CI) 9641 (− 20,068 to 39,351) −33,884 (− 56,976 to −
10,793)**
− 2366 (− 29,426 to 24,695) 2957 (−20,724 to 26,639)
Cohen’s d 0.19 1.12 0.06 0.01
SOD (USOD/mgPTN) 1.90 ± 0.99 2.44 ± 1.34 4.04 ± 2.33 4.60 ± 2.62 3.08 ± 1.74 3.06 ± 1.34 3.30 ± 1.23 3.90 ± 1.75
Log SOD (USOD/
mgPTN)b
1.34 ± 0.36 1.52 ± 0.38 1.96 ± 0.60 2.06 ± 0.57 1.68 ± 0.37 1.70 ± 0.29 1.77 ± 0.32 1.90 ± 0.42 0.095
Diff. Mean (95% CI) 0.18 (− 0.05 to 0.41) 0.11 (− 0.46 to 0.67) 0.02 (− 0.23 to 0.26) 0.13 (−0.20 to 0.45)
Cohen’s d 0.49 0.17 0.06 0.34
Values are presented as mean ± standard deviation. * Models were adjusted for age, gender, duration of diabetes and use of drugs, a Logarithmic transformation,
b Square root transformation, ** p = 0.004 compared to before supplementation
Abbreviations: hs-CRP high sensitivity C-reactive protein, TBARS thiobarbituric acid reactive substances, SOD superoxide dismutase
p value in bold was statiscally significant
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lipoperoxides as measured by TBARS and F2-Isoprostanes
(primary outcomes). If exercise intensity was to be an
issue, our data are corroborated by the findings of Davison
et al. [33], that did not observe differences in the concen-
trations of malondialdehyde even after strenuous exercise.
In addition, the lack of changes in TBARS and F2-
isoprostanes may be attributed, at least in part, by the
shorter period of supplementation of the present work in
comparison with others.
We hypothesized that including n-3 PUFA to our sub-
jects would induce benefits when they exercise at high in-
tensity, however, with except of changes in TRAP, our
intervention fail to change levels of lipoperoxidation, SOD
and UA. Accinni and colleagues [34] also found an in-
crease in TRAP in dyslipidemic volunteers supplemented
with n-3 PUFA for 4 months, however, with a significant
reduction in the levels of TBARS (P = 0,002). After treat-
ing healthy volunteers with 3.6 g/day of n-3 PUFA, Nalsen
et al. [16] did not observe changes in the values of TRAP;
however, they found a significant (P = 0.015) reduction in
lipoperoxidation as measured by F2-isoprostanes concen-
tration. The difference in results among studies may be re-
lated to different exercise protocols, duration of the tests,
and different methods employed when measuring the oxi-
dative stress markers.
Regarding SOD and UA, our secondary outcomes,
there were no significant changes after the exercise,
similarly to the results described by Laaksonen et al. [31]
and Atalay et al. [32]. If our subjects were more obese or
dyslipidemic, the results could be different (49). There is
still very limited information on the effects of exercise in
acute oxidative stress in subjects with type 2 diabetes.
The trend for increased activity of SOD after supple-
mentation with n-3 PUFA was not reported in the work
of Kesavulu et al. [4]. However, Smaoui et al. [35]
showed a positive correlation between SOD activity and
concentrations of n-3 PUFA in erythrocytes. Erdogan et
al. [36] also found increased activity of SOD in rats after
0.4 / kg body weight fish oil supplementation for 30 days.
This increase in SOD and TRAP could be explained by
the formation of cyclopentenone prostaglandins. Supple-
mentation with n-3 PUFA, particularly with EPA and
DHA, has been documented to trigger a momentary
lipoperoxidation process, thus leading to the formation
of prostaglandins, particularly cyclopentenone prosta-
glandins. These are responsible for the dissociation of
Keap1/Nrf2 (NF-E2-related factor). Nrf2 is the main
transcription factor for the activation of the expression
of antioxidant enzymes (e.g. SOD, catalase, glutathione
reductase) as well as phase 2 enzymes (e.g. glutathione
S-transferase, NADPH oxidase) and thus also increases
TRAP [37]. The production of lipoperoxide is not con-
sidered enough to cause damage to the body, but im-
portant to stimulate the defense systems.
Subjects who develop T2DM have high levels of inflam-
matory markers such as hs-CRP when compared to healthy
subjects [37, 38]. Supplementation with n-3 PUFA has been
suggested to minimize the inflammatory processes [39].
However, our study failed to detect any significant change
in the plasma levels of hs-CRP after supplementation with
n-3 PUFA. Our findings corroborate the data published by
Madsen et al. [40] who worked with healthy subjects sup-
plemented with 2 or 6.6 g / day of n-3 PUFA, for a period
of 12 weeks. Both groups showed no change in the values
of hs-CRP. Mori et al. [15] and Fatemeh Azizi-Soleiman et
al. [41] also found no change in plasma levels of CRP after
supplementation with EPA or DHA, for 6 weeks and
8 weeks, respectively, in type 2 diabetic subjects. Other
studies also have shown that either EPA or DHA reduce in
vivo oxidant stress without changing markers of inflamma-
tion, in treated, hypertensive, type 2 diabetic subjects [15].
Finally, despite the lack of changes of hs-CRP, we cannot
exclude the potential anti-inflammatory effects of our sup-
plementation, since we did not look at other inflammatory
markers such as TNF-α, IL-8, eHSP70 etc. This is a limita-
tion of our study.
Plasma glucose and HbA1c did not change significantly
after the period of supplementation. Some studies re-
ported increased levels of glucose, HbA1c and low insulin
activity, in type 2 diabetes, after the consumption of large
amounts of fish oil (around 10 g/day) [42]. However, when
of n-3 PUFA is given in smaller quantities (1 to 4 g/day),
no changes in glycemic parameters are observed [43]. In
our study, a significant reduction (17%) in the values of
plasma triglycerides was observed after the period of sup-
plementation with n-3 PUFA. These results can be ex-
plained by the reduction of fractions of VLDL - thus
minimizing the hepatic production of triglycerides - and a
possible reduction of free fatty acids [44]. As in other
studies, there were no significant changes in other lipid
parameters [43, 45–47]. This can be partially explained by
the fact that the diabetic subjects in the present study
were not dyslipidemic, and were relatively lean (over-
weight on average). This differs from many studies in the
literature. In a meta-analysis covering studies between
1966 and 2006, Hartweg et al. [48], showed that n-3 PUFA
supplementation is, indeed, efficient to reduce triglycer-
ides and VLDL levels, without changing other lipid sub
fractions. In contrast, Abe et al. [49], after 6 weeks of sup-
plementation with 4 g/day n-3 PUFA, found an 11% reduc-
tion in total cholesterol and a 14% increase in HDL. These
changes are not a consensus in the available literature. In
addition, a 4-h infusion of intralipid (n-3 FA) failed to affect
insulin sensitivity, insulin secretion, or markers of oxidative
stress in subjects with T2DM [50]. It could explain the lack
of changes in the glycemic profile.
To the best of our knowledge, this is the first
study to examine the interactions between n-3 PUFA
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supplementation and high-intensity exercise on oxi-
dative stress and inflammation in subjects with
T2DM. However, we recognize that the study has several
limitations. First, the sample size was small, although the ef-
fect size on the variables with statistical significance was
high. So, at this point, should be interpreted with caution
before being extrapolated to the general population. Sec-
ond, we have only studied acute effect of high intensity ex-
ercise; therefore, it is not possible to state that the effects
would be similar after other intensities of exercise. Finally,
we did not analyze the supplement offered to the partici-
pants, so we cannot be 100% sure if the product provides
the amount of n-3 PUFA. We believe in the suitability of
the company, but we suggest that future studies test the
product before the beginning of the trial. Despite some
limitations, the strength of this study is that we analyzed a
large number of variables related to oxidative stress, in-
cluding two measurements of lipoperoxidation (TBARS
and F2-siprostanes) and measurements of enzymatic
(SOD) and non-enzymatic antioxidants (uric acid and
TRAP). Thus, this study contributes to narrow the gap in
the literature on the effects of antioxidants nutrients in
oxidative stress parameters after acute exercise. Further
clarification is needed regarding the clinical relevance of
the n-3 PUFA supplementation for T2DM in different in-
tensities of exercise.
Conclusions
Eight weeks of supplementation with n-3 PUFA did
not attenuate oxidative stress parameters after a high
intensity exercise in T2DM subjects, with exception
to TRAP values. On the other hand, n-3 PUFA cause
reduction of triglyceride levels, at rest, without alter-
ing membrane oxidative damage or inflammation (as
assessed by hs-CRP). Studies including other inflam-
mation markers such as IL-8, MCP-1, eHSP70, or
others, are required to better assess this response.
Likewise, longer periods of observation and/or and
other intensities of exercise may be necessary to in-
duce significant increments in oxidative stress pa-
rameters in diabetic patients.
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